Home
Technology
Team
News
Contact
More
Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease
SCOHIA PHARMA & Kuria Therapeutics Announce Issuance of Key Patent Covering Novel Nrf2 Activator
Kuria Therapeutics Announces Close of Initial Fundraising Round to Develop SCO-116, A Novel Nrf2 Activator
Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator
